Basic Sinequan Information

• INN (International Nonproprietary Name): Doxepin.

• Brand Names Available In Australia: Doquel (capsules 10–100 mg) supplied by Aspen.

  Other international brands include Sinequan (capsules 10, 25, 50, 75, 100 mg; discontinued in the USA but generics available) and Silenor (tablets 3 mg and 6 mg for insomnia).

• ATC Code: N06AA12.

  This classifies doxepin as a tricyclic antidepressant (non‑selective monoamine reuptake inhibitor).

• Forms & Dosages: Capsules 10, 25, 50, 75, 100 mg; oral solution 10 mg/mL in some markets; Silenor tablets 3 mg and 6 mg for insomnia.

• Manufacturers In Australia: Aspen supplies Doquel in Australia.

  Generics are also commonly supplied worldwide by manufacturers such as Mylan and Teva.

• Registration Status In Australia: Registered as a prescription medicine (Rx) in Australia.

  Other markets show generics authorised and Sinequan discontinued in the USA while generics remain approved.

• OTC / Rx Classification: Prescription only (Rx).

  Doxepin is not available over the counter in major markets.

• Standard Dosages Per Condition: Depression/anxiety starting dose 75 mg/day (divided or at night); usual range 75–150 mg/day; maximum up to 300 mg/day.

  Insomnia (Silenor): 3–6 mg at bedtime.

• Dosage Adjustments: Use lower starting doses for the elderly (eg 25–50 mg/day) and reduce/titrate in hepatic or renal impairment.

• Treatment Durations & Regimens: Antidepressant effects may take 1–3 weeks; treatment often continues for months with periodic review.

  Insomnia dosing with Silenor is for short‑term use as clinically indicated.

• Missed Dose / Overdose: Take a missed dose when remembered unless it is near the next dose; do not double doses.

  Seek immediate medical attention for overdose—risks include severe drowsiness, cardiac arrhythmias and seizures.

• Storage & Transport: Store at room temperature (15–30°C), protect from moisture and excessive heat and transport in original packaging.

• Absolute Contraindications: Hypersensitivity to doxepin or other TCAs, narrow‑angle glaucoma, urinary retention and MAOI use within the past 14 days.

• Common Side Effects: Drowsiness, dry mouth, dizziness, blurred vision, constipation, urinary retention, weight gain and orthostatic hypotension.

Key Findings From Recent Trials

Major 2022–2025 Australian & Global Studies

Concerned about whether doxepin still has a role in modern practice?

Recent research and surveillance from 2022 to mid‑2024 show two clear themes: tricyclics like doxepin are less used first‑line for depression as SSRIs and SNRIs predominate, and low‑dose doxepin retains a steady niche for severe insomnia.

Australian observational datasets and international cohort studies confirm that TCAs remain effective for treatment‑resistant depression and neuropathic pain in selected patients.

Randomised controlled trials specifically separating doxepin from other TCAs remain limited in 2022–24, with much evidence coming from class trials, withdrawal designs and comparative reviews.

Main Outcomes

Worried whether patients will actually get better on doxepin?

Low‑dose doxepin (Silenor 3–6 mg) continues to show short‑term insomnia benefit over placebo, providing improved sleep onset and maintenance with predictable sedation at bedtime.

For antidepressant‑dose treatment, class‑level data support effectiveness in treatment‑resistant cases, although clinicians now more commonly reach for SSRIs or SNRIs first.

Safety Observations (TGA Reports)

Want to know the safety signals regulators are watching?

Pharmacovigilance summaries up to 2024, including TGA adverse event reporting trends, highlight anticholinergic effects, orthostatic hypotension and cardiac conduction abnormalities as the most clinically significant concerns.

These findings have led to conservative starting doses in older adults and recommendations for ECG monitoring when cardiac risk is present.

Clinical Mechanism Of Action

Layman’s Explanation

Are you asking how doxepin helps mood and sleep?

Doxepin is a tricyclic antidepressant that lifts mood by increasing certain brain chemicals and helps sleep by blocking histamine receptors at low doses.

At low nightly doses it mainly acts as a sedative, while at higher divided doses it provides antidepressant benefit.

Scientific Breakdown

Want the pharmacology in plain terms for clinical use?

Doxepin is classified under ATC N06AA12 as a non‑selective monoamine reuptake inhibitor.

It inhibits reuptake of serotonin and noradrenaline, increasing synaptic availability and producing antidepressant effects at higher plasma levels.

Strong H1 antihistamine activity explains pronounced sedation at low doses and underpins the licensed insomnia use of Silenor 3–6 mg tablets.

Anticholinergic (muscarinic) blockade accounts for dry mouth, constipation, urinary retention and cognitive slowing, while alpha‑1 adrenergic antagonism explains orthostatic hypotension.

Hepatic metabolism produces active metabolites and necessitates dose adjustments in hepatic impairment.

Scope Of Approved & Off‑Label Use

Australian Approvals (TGA‑Listed, PBS Inclusion)

Curious what doxepin is officially approved for in Australia?

Doxepin is a prescription‑only tricyclic antidepressant registered in Australia as Doquel capsules 10–100 mg.

Silenor (3–6 mg) is licensed internationally for insomnia but availability and PBS subsidy depend on formulation and listing status.

Prescribers should confirm current PBS Schedule entries for subsidy information before initiating therapy.

Notable Off‑Label Trends In Australian Practice

Wondering when Australian clinicians choose doxepin off‑label?

Low‑dose doxepin is sometimes used off‑label for chronic insomnia where benzodiazepines, z‑drugs or CBT‑I have failed or are unsuitable.

Specialist use for neuropathic pain or chronic pruritus is reported internationally due to the drug’s antihistaminic and central effects, but use in primary care is limited by tolerability concerns.

TGA guidance and local formularies recommend careful documentation and patient selection for off‑label prescribing.

Dosage Strategy

General Dosing

Not sure how to start or titrate doxepin safely?

For depression and anxiety, the common adult starting dose in product information is around 75 mg/day, given at night or divided, with a typical range of 75–150 mg/day and a maximum up to 300 mg/day.

Elderly patients should start at a much lower dose such as 25–50 mg/day because of increased sensitivity to anticholinergic and sedative effects.

For insomnia, Silenor tablets 3–6 mg at bedtime exploit the antihistamine effect rather than antidepressant reuptake blockade.

Condition‑Specific Dosing (PBS Recommendations)

Want practical PBS‑aware tips for rural or concessional patients?

Titrate slowly by 25–50 mg increments for antidepressant effect and reassess every 2–4 weeks, reducing step size in older or frail patients.

Check PBS item numbers to select a subsidised generic when available, and document rationale if prescribing a non‑PBS or higher dose formulation.

Adjust starting doses and titration speed for hepatic or renal impairment and provide clear follow‑up plans for monitoring.

Safety Protocols

Contraindications (Australian Guidelines)

Worried about who must not take doxepin?

Absolute contraindications include known hypersensitivity to doxepin or other TCAs, untreated narrow‑angle glaucoma, urinary retention and MAOI use within the last 14 days.

Relative contraindications include severe hepatic or renal impairment, significant cardiac conduction disorders, severe prostatic hypertrophy and pregnancy or lactation unless benefits clearly outweigh risks.

Adverse Effects (Post‑Market Pharmacovigilance)

Want to know the adverse events patients commonly report?

Common adverse effects are drowsiness, dry mouth, dizziness, blurred vision, constipation, urinary retention, weight gain and orthostatic hypotension.

TGA reports and international surveillance identify serious but less common events such as cardiac arrhythmias and seizures, and they underscore increased fall risk and cognitive side effects in older adults.

Safety protocols should include baseline ECG for patients with cardiac risk, medication reconciliation for anticholinergic burden and a deprescribing plan for therapy cessation.

Interaction Mapping

Food Interactions (Alcohol, Coffee, Diet In Australia)

Wondering what lifestyle advice to give to patients on doxepin?

Alcohol significantly increases CNS depression and sedation and should be avoided during initiation and dose changes.

Caffeine may blunt sedation but can aggravate anxiety or interfere with sleep; advise patients to monitor intake and keep dosing consistent relative to meals.

Drug Combinations To Avoid (TGA Safety Alerts)

Concerned about dangerous drug combinations?

Concomitant MAOI use (within 14 days) is contraindicated due to severe interactions.

Avoid combining doxepin with other strong anticholinergics and monitor closely if used with central sedatives such as benzodiazepines, opioids or gabapentinoids because of additive sedation and respiratory depression risk.

SSRIs and SNRIs can raise TCA plasma levels via CYP inhibition—consider dose reduction and ECG monitoring where appropriate.

Also avoid combinations with QT‑prolonging medicines where possible and conduct pharmacist review for strong CYP inhibitors or inducers.

Patient Experience Analysis

Australian Survey Data

Are patients happy with doxepin treatment?

Surveys and pharmacy counselling logs in Australia show mixed views: many patients using low‑dose doxepin report faster sleep onset and better sleep maintenance, while those on antidepressant doses often stop because of daytime sedation or anticholinergic side effects.

Pharmacy data indicate frequent counselling needs around drowsiness, orthostatic dizziness and potential interactions.

Forum And Pharmacy Trends

What do online communities and pharmacists notice most?

Online forums often express caution about TCAs in older adults and emphasise slow titration and monitoring for falls and cognitive changes.

Community pharmacists commonly advise switching to PBS‑subsidised generics to reduce cost and play an active role screening for falls risk, advising against alcohol and liaising with prescribers on dose adjustments.

Distribution & Pricing Landscape

National Pharmacy Chains (Chemist Warehouse, Priceline, TerryWhite)

How easy is it for patients to buy doxepin in Australia?

Doquel capsules and generics are distributed through community pharmacies and hospital formularies and are stocked by major chains such as Chemist Warehouse, Priceline and TerryWhite where supplied by wholesalers.

Pharmacies commonly stock generics from suppliers such as Mylan and Teva when available.

Online Pharmacy Growth And Telehealth E‑Scripts

Can patients use telehealth to get doxepin?

Telehealth e‑prescriptions and online pharmacy ordering have accelerated access in metropolitan areas, while rural patients still depend on local dispensing or mail‑order deliveries.

Our online pharmacy can arrange discreet delivery across Australia with valid prescriptions and typical timelines in the delivery table below.

PBS Vs Private Cost Comparisons

Worried about out‑of‑pocket costs?

PBS subsidy varies by formulation and indication, so prescribers and pharmacists should verify current listings before prescribing.

Where PBS does not cover a specific brand—such as an imported or branded Silenor preparation—private costs can be higher and pharmacists often recommend switching to an equivalent PBS‑listed generic to reduce cost.

Alternative Options

Comparison Summary Of PBS And Non‑PBS Options

Thinking whether doxepin is the best choice for your patient?

For depression and anxiety, SSRIs such as sertraline and escitalopram and SNRIs are generally first‑line in Australian guidelines because of more favourable tolerability and safety in overdose.

For insomnia, low‑dose doxepin (Silenor 3–6 mg) is an option alongside mirtazapine at low doses, short‑term z‑drugs and cognitive behavioural therapy for insomnia (CBT‑I).

PBS‑listed SSRIs often have broader subsidy and are common in primary care, while branded Silenor may be non‑PBS and cost more privately.

Pros And Cons Checklist

Need a quick decision aid?

• Pros: Effective in treatment‑resistant depression, reliable sedative action at low doses, generic availability (Doquel) where PBS listed.

• Cons: Anticholinergic burden, orthostatic hypotension, cardiac conduction risk and generally not preferred for older adults.

• Choice should be individualised, taking comorbidities, PBS access and patient preference into account.

Regulatory Status

TGA Approval Framework

Want to check official approvals and safety alerts?

Doxepin (Doquel) is registered in Australia as a prescription medicine and is regulated under the TGA framework for quality, safety and efficacy.

The TGA maintains a post‑market surveillance system and issues safety communications when new data emerge.

PBS Subsidy Process

How does a medicine get on the PBS?

PBS listing requires an application to PBAC showing clinical benefit and cost‑effectiveness, and decisions dictate subsidy and patient copayment levels.

Some doxepin strengths or branded formulations may not be PBS‑subsidised, so prescribers should check the PBS Schedule and pharmacists should offer PBS‑listed alternatives to reduce cost.

Consolidated FAQ

Here are common patient questions seen in Australian practice.

1. Is doxepin on the PBS?

   Some doxepin formulations are available as generics and may be PBS‑subsidised depending on strength and indication; check the current PBS Schedule or ask your pharmacist.

2. Can I drink alcohol while taking doxepin?

   No—alcohol increases sedation and fall risk; abstain during initiation and dose changes.

3. Is doxepin safe for older adults?

   Use caution; start at lower doses (for example 25–50 mg/day for antidepressant dosing) and consider alternatives due to anticholinergic sensitivity and fall risk.

4. What should I do if I miss a dose?

   Take the missed dose when you remember unless it is close to the next dose; do not double up.

5. Can I get doxepin online or without a prescription?

   Doxepin is prescription‑only in Australia; obtain it via a valid GP or telehealth e‑script from a legitimate provider and fill at an authorised pharmacy.

Visual Guide

Want useful visuals for patients and the pharmacy team?

Recommended infographic panels include a bar chart comparing typical PBS pricing for generic doxepin versus private cost for branded Silenor, a distribution heatmap showing metro versus rural pharmacy density and mail‑order timelines, and a product snapshot listing INN, ATC code, and common strengths.

Safety iconography should highlight ECG requirement for at‑risk patients, anticholinergic side effects to watch for, alcohol avoidance and fall precautions.

Include source citations such as TGA and PBS product information where permitted and provide a printable counselling card summarising dose, interactions and emergency actions for overdose.

Storage & Transport

Household Storage Under Australian Climate

Worried about storing doxepin in hot or humid weather?

Store doxepin at room temperature between 15°C and 30°C, protect from moisture and excessive heat and keep it out of sunlight.

In hot or humid regions avoid bathroom storage and use a cool, dry cupboard away from children.

Cold‑Chain Logistics For Pharmacies

Do pharmacies need special cold‑chain arrangements?

Standard doxepin capsules and Silenor tablets do not require cold‑chain storage, but stock should be protected from extreme heat during storage and transit.

Pharmacies receiving long transit deliveries should inspect batches for heat damage and check expiry dates upon receipt and report suspected storage problems through normal channels.

Delivery Across Australia

Guidelines For Proper Use

Pharmacist Counselling Style In Australia

Want a concise script for counselling patients starting doxepin?

Begin by confirming the indication and the prescribed dose—clarify whether the prescription is for low‑dose insomnia (Silenor 3–6 mg) or antidepressant dosing (eg Doquel capsules 75 mg/day starter).

Emphasise alcohol avoidance, orthostatic precautions and typical anticholinergic side effects such as dry mouth and constipation.

Screen for urinary retention, glaucoma and cardiac history, and review current medicines for anticholinergic or QT‑prolonging interactions.

Suggest pillboxes or dose reminders for patients with adherence concerns and arrange follow up within 1–2 weeks for tolerability checks.

National Health Authority Recommendations

What do national guidelines recommend about doxepin?

Align prescribing with TGA product information and national clinical guidelines that typically favour SSRIs/SNRIs as first‑line for depression and reserve TCAs like doxepin for treatment‑resistant cases or where sedative antihistaminic properties are specifically desired.

Use the lowest effective dose, taper gradually to discontinue and report adverse events to the TGA as part of pharmacovigilance.

Coordinate care among GP, psychiatrist and pharmacist for complex patients, especially the elderly or those in aged‑care settings.